Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07654257 · ClinicalTrials.gov registry record · Phase 2
Single FrAction Interstitial BreaSt BracHytherApy
A Phase 2 study, sponsored by Virginia Commonwealth University.
- Not yet
- Registry status
- Phase 2
- Development phase
- 134
- Enrollment target
NCT07654257: Clinical Trial Phase 2 study, sponsored by Virginia Commonwealth University.
NCT07654257 is a Phase 2 study that has not yet begun recruiting, run by Virginia Commonwealth University. The registered enrollment target is 134 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07654257, a Phase 2 study, has not yet begun recruiting, sponsored by Virginia Commonwealth University.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 134 participants
- Enrollment target
Study Summary
This phase 2, single arm prospective study has been designed to determine the safety of delivering accelerated partial breast irradiation (APBI) with a multicatheter interstitial implant in a single fraction over 1 day. This is a method of delivering radiation therapy directly into or close to a tumor.
Primary Outcome
Incidence of accelerated partial breast irradiation (APBI) related toxicities of interest occurring at grade ≥3 at 1, 3, and 5 years after APBI. The descriptions and grading scales found in the The National Cancer Institutes' (NCI) Common Terminology Criteria for Adverse Events is a descriptive terminology (CTCAE), a list of standardized definitions for adverse events, revised v6.0 will be utilized for adverse (AE) (toxicity) reporting.
Interventions
- DRUG Partial Breast Irradiation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 134 participants |
| Start Date | 2026-09-01 |
| Est. Completion | 2036-09-30 |
| Phase | Phase 2 |
What is known before NCT07654257 opens enrollment
NCT07654257 is an interventional study that assigns participants to a tested intervention. The registered 134 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 0 conditions, and to 1 intervention - of which Partial Breast Irradiation is the first listed.
NCT07654257 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07654257 about?
NCT07654257 is a clinical study titled "Single FrAction Interstitial BreaSt BracHytherApy". This phase 2, single arm prospective study has been designed to determine the safety of delivering accelerated partial breast irradiation (APBI) with a multicatheter interstitial implant in a single fraction over 1 day. This is a method of delivering radiation therapy directly into or close to a tum...
What is the current status of trial NCT07654257?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 134 participants. The study started on 2026-09-01. Estimated completion is 2036-09-30.
What interventions are being tested in trial NCT07654257?
The interventions under investigation include: Partial Breast Irradiation (DRUG).
Who is sponsoring clinical trial NCT07654257?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07654257's enrollment target sits among peer trials
134 537th of 2000 higher than 1,463 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02469662 · 134 participants · NA
Clinical Outcomes Study of the Nexel Total Elbow
- NCT03110822 · 134 participants · Phase 1
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
- NCT04678648 · 134 participants · Phase 1
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
- NCT05264857 · 134 participants · NA
Decision Aid and Thyroid Nodules Management
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI